Ph.D FESC,FACC,FAHA,FACP. Global Physician Association Member at Cleveland Clinic Florida ,Ex-professorOf Post Graduate FCM UNICAMP Oral Semaglutide in Type 2 Diabetes: Robust Glycemic Control With Added Cardiometabolic Benefits Key Statistical Outcomes (PIONEER Program): HbA1c reduction: 0.6% to 1.4% at 26 weeks versus placebo
Popular combinations include peptides with medical weight loss programs for enhanced results, Botox and fillers for comprehensive anti-aging, and HydraFacial to support skin benefits from GLOW peptide
Caution with insulin/sulfonylureas, gallbladder disease, diabetic retinopathy, and significant kidney disease
It may represent a threshold phenomenon that emerges only at higher exposure
Dou Y, Lee A, Zhu L, Morton J, Ladiges W